1.
|
Phase: Phase II Type: Treatment Status: Closed Age: 12 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SG035-0003, 2008-006034-10, NCT00848926
|
|
2.
|
Phase: Phase II Type: Treatment Status: Closed Age: 12 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SG035-0004, 2008-006035-12, NCT00866047
|
|
3.
|
Phase: Phase II Type: Treatment Status: Enrolling by invitation Age: 12 to 120 Sponsor: Pharmaceutical / Industry Protocol IDs: SGN35-006, NCT00947856
|
|
4.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SG035-0001, NCT00430846
|
|
5.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SGN35-007, NCT01026233
|
|
6.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Enrolling by invitation Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SGN35-008, NCT01026415
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: SGN35-009, NCT01060904
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SGN35-011, 2010-022839-11, NCT01309789
|
|
9.
|
Phase: No phase specified Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SGN35-010, NCT01196208
|